Pacific Biosciences Of California (PACB) Return on Equity (2011 - 2026)

Pacific Biosciences Of California has reported Return on Equity for 16 years, with the latest figure at 0.33% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 31.0% year-over-year to 0.33%; the trailing twelve-month figure through Mar 2026 stood at 0.33% (down 31.0% YoY), and the FY2025 full-year result was 0.02%, down 2.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.33%, down from 0.26% in the prior quarter.
• The five-year high for Return on Equity was 0.0% in Q1 2022, with the low at 0.33% in Q1 2026.
• Average Return on Equity over 5 years is 0.05%, with a median of 0.01% recorded in 2022.
• Year-over-year, Return on Equity changed 0 bps in 2022 and sank 31 bps in 2026.
• Tracing PACB's Return on Equity over 5 years: stood at 0.01% in 2022, then climbed by 21 bps to 0.0% in 2023, then plunged by 54 bps to 0.01% in 2024, then slumped by 3984 bps to 0.26% in 2025, then slipped by 26 bps to 0.33% in 2026.
• The last three Return on Equity figures came in at 0.33% (Q1 2026), 0.26% (Q4 2025), and 0.1% (Q3 2025), per Business Quant data.

Peer Comparison